Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Summer;4(2):90-7.
doi: 10.7508/aojnmb.2016.02.005.

Physiologically Based Pharmacokinetic (PBPK) Model for Biodistribution of Radiolabeled Peptides in Patients with Neuroendocrine Tumours

Radovan Gospavic  1 , Peter Knoll  2 , Siroos Mirzaei  2 , Viktor Popov  3
Affiliations

Physiologically Based Pharmacokinetic (PBPK) Model for Biodistribution of Radiolabeled Peptides in Patients with Neuroendocrine Tumours

Radovan Gospavic et al. Asia Ocean J Nucl Med Biol. 2016 Summer.

Abstract

Objectives: The objectives of this work was to assess the benefits of the application of Physiologically Based Pharmacokinetic (PBPK) models in patients with different neuroendocrine tumours (NET) who were treated with Lu-177 DOTATATE. The model utilises clinical data on biodistribution of radiolabeled peptides (RLPs) obtained by whole body scintigraphy (WBS) of the patients.

Methods: The blood flow restricted (perfusion rate limited) type of the PBPK model for biodistribution of radiolabeled peptides (RLPs) in individual human organs is based on the multi-compartment approach, which takes into account the main physiological processes in the organism: absorption, distribution, metabolism and excretion (ADME). The approach calibrates the PBPK model for each patient in order to increase the accuracy of the dose estimation. Datasets obtained using WBS in four patients have been used to obtain the unknown model parameters. The scintigraphic data were acquired using a double head gamma camera in patients with different neuroendocrine tumours who were treated with Lu-177 DOTATATE. The activity administered to each patient was 7400 MBq.

Results: Satisfactory agreement of the model predictions with the data obtained from the WBS for each patient has been achieved.

Conclusion: The study indicates that the PBPK model can be used for more accurate calculation of biodistribution and absorbed doses in patients. This approach is the first attempt of utilizing scintigraphic data in PBPK models, which was obtained during Lu-177 peptide therapy of patients with NET.

Keywords: Lu-177 DOTATATE; PBPK model; Radiolabeled peptides; Whole body scintigraphy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Whole body image showing radiotracer distribution in different regions of interests (ROI) over brain, lungs, kidneys and liver
Figure 2
Figure 2
Schematic diagram for multi compartment PBPK model for biodistribution of Lu-177 DOTATATE in human body
Figure 3
Figure 3
Comparison of time-activity curves in liver for patient 1, obtained by WBS and PBPK model
Figure 4
Figure 4
Comparison of time-activity curve in kidney for patient 1, obtained by WBS and PBPK model
Figure 5
Figure 5
Comparison of time-activity curve in liver for patient 2, obtained by WBS and PBPK model
Figure 6
Figure 6
Comparison of time-activity curve in kidney for patient 2, obtained by WBS and PBPK model
Figure 7
Figure 7
Comparison of time-activity curve in liver for patient 3, obtained by WBS and PBPK model
Figure 8
Figure 8
Comparison of time-activity curve in kidney for patient 3, obtained by WBS and PBPK model
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Theil FP, Guentert TW, Haddad S, Poulin P. Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol Lett. 2003;138(1-2):29–49. - PubMed
    1. Lee HA, Leavens TL, Mason SE, Monteiro-Riviere NA, Riviere JE. Comparison of quantum dot biodistribution with a blood-flow-limited physiologically based pharmacokinetic model. Nano Lett. 2009;9(2):794–9. - PubMed
    1. Baxter LT, Zhu H, Mackensen DG, Butler WF, Jain RK. Biodistribution of monoclonal antibodies:scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res. 1995;55(20):4611–22. - PubMed
    1. Baxter LT, Zhu H, Mackensen DG, Jain RK. physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res. 1994;54(6):1517–28. - PubMed
    1. Adams JC, Dills RL, Morgan MS, Kalman DA, Pierce CH. A physiologically based toxicokinetic model of inhalation exposure to xylenes in Caucasian men. Regul Toxicol Pharmacol. 2005;43(2):203–14. - PubMed

LinkOut - more resources